Skip to main content
Advertisement
Advertisement

ACRS

ACRS logo

Aclaris Therapeutics, Inc.

5.17
USD
Sponsored
-0.55
-9.67%
Sep 23, 15:54 UTC -4
Open

ACRS Earnings Reports

Positive Surprise Ratio

ACRS beat 30 of 43 last estimates.

70%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.32M
/
-$0.16
Implied change from Q2 26 (Revenue/ EPS)
-18.73%
/
+6.67%
Implied change from Q3 25 (Revenue/ EPS)
-59.87%
/
+33.33%

Aclaris Therapeutics, Inc. earnings per share and revenue

On Aug 06, 2026, ACRS reported earnings of -0.15 USD per share (EPS) for Q2 26, beating the estimate of -0.16 USD, resulting in a 8.09% surprise. Revenue reached 1.63 million, compared to an expected 1.41 million, with a 15.49% difference. The market reacted with a -4.25% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 1.32 million USD, implying an increase of 6.67% EPS, and decrease of -18.73% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Aclaris Therapeutics, Inc. reported EPS of -$0.15, beating estimates by 8.09%, and revenue of $1.63M, 15.49% above expectations.
The stock price moved down -4.25%, changed from $6.36 before the earnings release to $6.09 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 6 analysts, Aclaris Therapeutics, Inc. is expected to report EPS of -$0.16 and revenue of $1.32M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement